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Abstract
Background
Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivi-
rals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin
(PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-
used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with
telaprevir (TVR)+PR.
Study design
Mathematical modeling of ALT and HCV-RNA kinetics was performed in 111 HCV-1 cir-
rhotic patients, 81 treated with all-DAA regimens and 30 with TVR+PR. Kinetic-models and
Cox-analysis were used to assess determinants of ALT-decay and normalization.
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Results
HCV-RNA kinetics was biphasic, reflecting a mean effectiveness in blocking viral production
>99.8%. The first-phase of viral-decline was faster in patients receiving NS5A-inhibitors
compared to TVR+PR or sofosbuvir+simeprevir (p<0.001), reflecting higher efficacy in
blocking assembly/secretion. The second-phase, noted δ and attributed to infected-cell
loss, was faster in patients receiving TVR+PR or sofosbuvir+simeprevir compared to NS5A-
inhibitors (0.27 vs 0.21 d-1, respectively, p = 0.0012). In contrast the rate of ALT-normaliza-
tion, noted λ, was slower in patients receiving TVR+PR or sofosbuvir+simeprevir compared
to NS5A-inhibitors (0.17 vs 0.27 d-1, respectively, p<0.001). There was no significant associ-
ation between the second-phase of viral-decline and ALT normalization rate and, for a given
level of viral reduction, ALT-normalization was more profound in patients receiving DAA,
and NS5A in particular, than TVR+PR.
Conclusions
Our data support a process of HCV-clearance by all-DAA regimens potentiated by NS5A-
inhibitor, and less relying upon hepatocyte death than IFN-containing regimens. This
may underline a process of “cell-cure” by DAAs, leading to a fast improvement of liver
homeostasis.
Introduction
In 1998 Neumann and his colleagues proposed a seminal model to explain the biphasic decline
of HCV-RNA after initiation of interferon (IFN)[1]. According to this model, the rapid viral-
load decline in the first days of treatment depends upon virus clearance from plasma, with a
magnitude reflecting the treatment effectiveness in blocking viral production. After this rapid
“first-phase”, a slower”second-phase” ensues, consistent with progressive elimination of
infected hepatocytes.
In the last 20 years, this initial model was expanded to include novel ideas[2–5], and novel
drugs. One important point raised by scientists was that the second-phase of viral kinetics dur-
ing direct-acting antivirals (DAAs) treatment may not only represent cell-elimination, but
may also be associated with the progressive reduction of the intracellular viral content, down
to its disappearance (i.e. “cell-cure”)[6–8]. This possibility was supported by experiments in
vitro[9] and by the clinical observation that the second-phase with DAAs was faster than dur-
ing IFN-based therapy, and no increase in Alanine Amino Transferases (ALT) levels was
observed[7, 10].
ALT levels can be considered as a surrogate marker for cell-death, since hepatic injury
causes their leak from damaged hepatocytes and their increase in serum[11]. Since IFN-activ-
ity includes cell-death, it was not uncommon to observed suboptimal ALT decline, and
infrequent ALT-normalization, during IFN-treatment, especially in patients with more com-
promised liver status[12].
Consistently with the idea of a “cell-cure” by DAAs, ALT kinetics is thus supposed to be
improved. Telaprevir (TVR) indeed allowed ALT-normalization in 62% of patients by day-9
when used in monotherapy (vs. 33% when used with pegIFN and ribavirin [PR])[13], and the
IFN-free association of SOF+ledipasvir+GS9669/GS-9451 allowed ALT reduction to normal
levels by day-14 in 90% of patients[14]. Nevertheless, no data are available on ALT kinetics
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with currently-used DAA combinations in clinics, nor on the impact of cirrhosis, making diffi-
cult to appreciate the role of all-DAA combinations in the more complex patients seen in real-
world practice.
Here, in order to better understand the effect of DAA combinations, we compared the
kinetics of both ALT and HCV-RNA in cirrhotic-patients treated with various DAA-based
regimens, with or without IFN, for whom frequent measurements of both markers were avail-
able. We used the techniques of mathematical modeling to recapitulate the kinetics observed
and better understand the origin of possible differences across treatment-regimens.
Materials and methods
Study population
Adults aged18 years with genotype-1 infection and cirrhosis, receiving one DAAs with or
without IFN were included if had: a) baseline and week-4 HCV-RNA and ALT available; b) at
least one HCV-RNA determination within the first 6 days of treatment, and one HCV-RNA
and ALT determination at week-1 and/or at week-2; c) high baseline ALT (>55 IU/ml in
men;>45 IU/ml in women). Patients who prematurely ended treatment before week-4 were
excluded.
Cirrhosis was documented by liver-biopsy or Fibroscan (12.5 KPa).
Detailed information on sampling and laboratory analyses are reported in S1 Supplementary
Material.
Approval by the local Ethics Committees of Fondazione PTV Policlinico Tor Vergata and
patient written informed consent were obtained. This study was conducted in accordance with
the principles of the Declaration of Helsinki. All information were recorded in an anonymous
database.
Statistical analysis
Results were compared using Spearman’s rank correlation test, Mann-Whitney U-test, Fisher
exact test or Chi2 test.
Cox regression analysis was performed using the following confounding variables: IFN-
administration, HCV-subtype, baseline ALT, NS5A-inhibitors administration, HCV-RNA
decay baseline-2 weeks, baseline HCV-RNA, previous IFN-experience (relapse, no-response,
other), previous PI-failure, IL-28B CC genotype, and ribavirin co-administration. Only vari-
ables having a p-value <0.10 in univariate analysis were included in multivariable analysis. To
avoid statistical multicollinearity, IFN and NS5A-administration were analyzed separately. Sta-
tistical significance threshold was set at 0.050.
All statistical analyses were performed using the open source environment R and SPSS soft-
ware package (SPSS Inc., Chicago, Illinois).
Mathematical modeling of early HCV-RNA and ALT kinetics
As we focused on early HCV-RNA and ALT kinetics, only data obtained during the first 4
weeks of treatment were analyzed. Data below LLOQ were taken into account using the
extended SAEM algorithm implemented in MONOLIX 4.3.3.
HCV-RNA and ALT kinetics were analyzed separately using nonlinear mixed-effect mod-
els, optimized according to significant covariates as described in S1 Supplementary Material.
To illustrate the difference in the virological and biological response across the covariates,
we simulated 1000 individual profiles from the final parameter estimates.
Viral and ALT kinetics during anti-HCV treatment with DAAs
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On the best model for viral and ALT kinetics containing only significant covariates, the cor-
relation between viral and ALT kinetic parameters, stratified or not on the different treatment
groups, was studied using Spearman correlation test. A joint model that would simultaneously
fit HCV-RNA and ALT kinetic was considered relevant if at least one correlation coefficient
was>0.4.
Results
Characteristics of the study population
111 patients met the inclusion criteria (Table 1), of whom 81 treated with an all-DAAs regi-
men: 32 with paritaprevir/r+ombitasvir+dasabuvir (3D); 9 with daclatasvir+asunaprevir
(DCV+ASU); 5 with DCV+SOF; and 35 with simeprevir (SIM)+SOF. In addition, 30 patients
received TVR+PR. Ribavirin was co-administered in all patients treated with 3D, in 60% of
patients treated with DCV+SOF or SOF+SIM.
A sustained virological response (SVR12) was achieved in 76/81 (93.8%) all-DAA patients
and in 20/30 TVR+PR patients (66.7%, p<0.001) (Fig 1 panel A). Among TVR+PR patients, 9
Table 1. Characteristics of the study population.
IFN-free, all-DAA regimens Telaprevir and
pegIFN
P-
valueaParitaprevir,
ombitasvir and
dasabuvir
Daclatasvir and
asunaprevir
Daclatasvir and
sofosbuvir
Sofosbuvir and
simeprevir
Patients, N 32 9 5 35 30
HCV genotype, N
(%)
1a 8 (25.0) 0 (0.0) 2 (40.0) 20 (57.1) 13 (43.3) 0.545
1b 24 (75.0) 9 (100) 3 (60.0) 15 (42.9) 17 (56.7)
Males, N(%) 23 (71.9) 6 (66.7) 4 (80.0) 24 (68.6) 22 (73.3) 0.760
Age (years), Median (IQR) 58 (53–65) 65 (56–68) 53 (50–54) 56 (51–64) 55 (51–63) 0.300
Stiffness at baseline (Kpa),
Median (IQR)b
26.7 (17.3–33.8) 28.4 (16–31) 22.8 (12.1–72) 20.4 (16.6–27.7) 21 (19–26) 0.367
Naive patients, N(%) 6 (18.8) 1 (11.1) 1 (20.0) 8 (22.9) 7 (23.3) 0.793
Treatment
experience, N(%)
Non
responder
17 (53.1) 6 (66.7) 2 (40.0) 17 (48.6) 15 (50) 1.000
Relapser 7 (21.9) 2 (22.2) 2 (40.0) 5 (14.3) 8 (26.7) 0.445
Breakthrough 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.7) 0 (0.0) 1.000
Other 2 (6.3) 0 (0.0) 0 (0.0) 3 (8.6) 0 (0.0) 0.321
PI experienced, N(%) 2 (6.3) 0 (0.0) 1 (20.0) 5 (14.3) 0 (0.0) 0.074
RBV administration, N(%) 32 (100) 0 (0.0) 3 (60.0) 21 (60.0) 30 (100) 0.001
Baseline HCV-RNA (logIU/ml),
Median (IQR)
5.5 (5.1–6) 5.8 (5.4–6.1) 5.5 (5.3–6.3) 5.8 (5.2–6.2) 6.0 (5.7–6.7) 0.006
Baseline ALT (IU/ml), Median
(IQR)
74 (60–127) 118 (70–155) 111 (102–139) 96 (77–166) 95 (65–144) 0.963
Baseline AST (IU/ml), Median
(IQR)
85 (63–125) 133 (91–170) 128 (122–134) 96 (72–129) 72 (51–100) 0.015
SVR12, N (%) 32 (100) 8 (88.9) 4 (80.0) 32 (91.4) 20 (66.7) <0.001
a P-values were calculated by Fisher exact test for categorical variables and by Mann-Whitney test for continuous variables. The comparison was
performed for telaprevir and pegIFN patients vs. all DAA-treated patients.
b Baseline stiffness value was available for 30 paritaprevir, ombitasvir and dasabuvir treated patients, 9 daclatasvir and asunaprevir patients, 3 daclatasvir
and sofosbuvir patients, 29 sofosbuvir and simeprevir patients, and 21 telaprevir and pegIFN treated patients.
ALT, alanine transaminase; AST, aspartate aminotransferase; DAAs, Direct Acting Antivirals; HCV, hepatitis C virus; IFN, interferon; IQR, interquartile
range; PI, protease inhibitor; RBV, ribavirin; SVR12, sustained virological response after 12 weeks of follow-up.
https://doi.org/10.1371/journal.pone.0177352.t001
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discontinued treatment prematurely for virological reasons: 3 according to stopping-rules for
partial-response, and 6 for virological-breakthrough. Overall, 6 patients relapsed: 1 treated
with DCV+ASU, 1 with DCV+SOF, 3 with SOF+SIM and 1 with TVR+PR. Six patients ended
all-DAA treatment with HCV-RNA detectable but not quantifiable, and were eventually
SVR12.
All-DAA and TVR+PR populations had comparable median (IQR) baseline ALT values (96
[9–138] vs. 95 [65–144], respectively; p = 0.963), and liver stiffness (23.6 [16.5–31.6] vs. 21.0
[19.0–26.0] kPA, respectively; p = 0.367). At least 1 baseline RAS (in relation to the actual regi-
men) was found in 22/91 (24.2%) all-oral treated patients, of whom 17 were infected with GT-
1b and 5 with GT-1a.
Patterns of HCV-RNA and ALT decay during and after antiviral treatment
In the first 4 weeks of treatment, a fast first-phase HCV-RNA decline in serum, followed by a
slower second-phase, was observed in all 111 patients analyzed (Fig 1, panels A and B). No sig-
nificant differences were found in HCV-RNA response rates among all-DAA and TVR+PR
treated patients, at least until day-28 (Fig 1, panel C). On the contrary, and despite comparable
baseline ALT values, TVR+PR patients showed a more heterogeneous, and generally subopti-
mal ALT decline compared to all-DAA patients (Fig 1, panels B). Indeed, all-DAAs treatment
led to ALT normalization in 85.0% of patients after only 14 days, and in 93.8% after 28 days,
while only 65.5% of TVR+PR patients had normal ALT at day-14 (p = 0.02), and 73.3% at day-
28 (p = 0.001). The achievement of healthy ALT during treatment required a median (IQR) of
Fig 1. Biphasic kinetics of HCV-RNA decay, and ALT drop during all-DAA and TVR+PR treatment and
follow-up. In upper panels, median values with 95% confidence interval of HCV-RNA (black dots) and ALT
(grey squares) during all-DAAs (panel A) and TVR+PR (panel B) treatment are reported. End of follow-up is at
12 weeks after treatment discontinuation. Black dotted line represents the lower limit of detection of HCV-RNA
(12–15 IU/ml). Grey dotted line represents normality range of ALT values in females (45 IU/ml). Histograms in
lower panels represent the percentages of patients with HCV-RNA below the lower limit of detection (panel C)
and with normal ALT values (panel D) during all-DAAs (black) and TVR+PR (grey) treatment. Normal ALT
values were considered as <55 IU/ml in men, and <45 IU/ml in women. ALT, alanine transaminase; DAA,
direct-acting antivirals; EOT, end of treatment; IU, international units; LLOD, lower limit of detection (<12–15
IU/ml, not detected); PR, pegylated interferon and ribavirin; TVR, telaprevir. * p-value <0.05 by Fisher exact
test; ** p-value0.001 by Fisher exact test.
https://doi.org/10.1371/journal.pone.0177352.g001
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7 (7–14) days for all-DAA patients, vs. 14 (14–39) in TVR+PR patients, even though this esti-
mation can be affected by different sampling times.
Between day-28 and the end of treatment (EOT), 7/28 (25%) TVR+PR patients showed a
re-alteration of ALT values after normalization, vs. 1/77 (1.3%) all-DAA patients (p<0.001)
(data not shown). At EOT, 97.4% of all-DAA patients had normal ALT values, vs. only 50.0%
of TVR+PR patients (p<0.001).
After 12 weeks since treatment discontinuation, the proportion of patients with normal
ALT values among those who had received IFN increased form 50% to 73.1%, vs. 91.9% of all-
DAA patients (p<0.001) (Fig 1, panel D). At the last follow-up available after SVR (median
[IQR] since treatment end = 91 [84–165] days), 65/69 all-DAA and all 13 TVR+PR patients
had healthy ALT.
ALT normalization rates at EOT were not significantly affected by baseline RASs presence
(p = 0.510), nor were SVR rates (p = 0.386), not even in patients with baseline HCV-RNA >
800.000 IU/ml (p = 0.152).
Impact of different DAA-combinations on modeled HCV-RNA kinetics
The kinetics of HCV-RNA decline was well described by a standard biphasic model, whose
population-parameters are reported in Table 2.
Table 2. Population kinetic parameters for the best HCV and ALT kinetic model.
Parametersa Fixed effect (RSE%) p-value Standard deviation (RSE%)
HCV-RNA Biphasic model
VL0
(logIU/ml)
GT 1a 5.98 (2) 0.00086 0.099 (7)
GT 1b 5.61 (1)
c
(/day)
NS5A-containing 7.88 (8) 0.00071 0.34 (15)
SOF+SMV and TVR+PR 5.28 (9)
δ
(/day)
NS5A-containing 0.21 (6) 0.0012 0.415 (8)
NS5A-free 0.27 (5)
ε All-DAA 0.998 (2) 0.01 0.16 (10)
TVR+PR 0.999 (4)
Additive residual errors 0.288 (4)
ALT Monophasic model
ALT0
(IU/mL)
103 (4) 0.42 (8)
ALTss
(IU/mL)
All-DAA 26.3 (9) 2.4 x 10−7 0.48 (8)
TVR+PR 43.4 (6)
λ
(/day)
NS5A-containing 0.27 (8) 0.30 (25)
NS5A-free 0.17 (8) 0.00015
Correlation ηALTss, ηALT0 0.57 (14)
Proportional residual errors 0.21 (5)
RSE, residual standard error; VL, viral load; IU, international units; GT, genotype; DCV, daclatasvir; ASV, asunaprevir; 3D, paritaprevir/ritonavir, ombitasvir
and dasabuvir; RBV, ribavirin; SOF, sofosbuvir; SMV, simeprevir; TVR, telaprevir; PR, pegylated interferon and ribavirin; ALT, alanine transaminase; DAA,
direct-acting antivirals
aInfected hepatocytes are cleared with a rate δ. The free virions V are released from the infected cells at a rate ρ, infect the target cells at a rate β and are
cleared from the circulation with a rate c. Antivirals block the production of new virus with an effectiveness ε. ALT0 represent baseline ALT, while ALTss
represent ALT values at steady-stade, represented by week-4 value in this study; λ is the rate of ALT decline from the baseline to a new lower set point
value after treatment initiation.
https://doi.org/10.1371/journal.pone.0177352.t002
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The mean effectiveness of antiviral treatment (ε) was 99.8% and 99.9% in patients treated
with all-DAA or TVR+PR treatments, respectively (p = 0.01). Among the tested covariates (see
Methods) NS5A-inhibitors significantly affected the clearance of free-virus (c) and the loss
rate of infected-cells (δ). Indeed, patients receiving a NS5A-inhibitor had a faster rate of viral-
clearance (7.88 vs. 5.28 d-1 in NS5A-free; p<0.001), and a lower rate of loss of infected-cells
(0.21 vs. 0.273 d-1 in NS5A-free; p = 0.0012). Thus, NS5A-inhibitors were associated with a
more rapid first-phase decay of HCV-RNA, but a slower second-phase, as can be seen by the
kinetics obtained by simulation in Fig 2, panel A.
Impact of different DAA-combinations on ALT kinetics
By Cox analysis, the use of IFN and of NS5A-free regimens were associated with higher risk of
not achieving normal ALT values before EOT (both p<0.0001), even after normalization for
several confounding variables (Table 3).
Notably, by mathematical modelling the rate of ALT decline (λ) was significantly lower in
NS5A-free regimens than in NS5A-containing (0.17 vs. 0.27 d-1, respectively; p<0.001), with
no significant difference in TVR+PR patients and those receiving SOF+SIM (Table 2). How-
ever, on the long run, IFN-treated patients had a significantly higher ALT steady state (ALTss),
than those receiving IFN-free regimens (43.4 vs. 26.3 IU/mL; p<0.001), regardless of NS5A-
inhibitors administration. Typical patterns of ALT kinetics in the different treatment groups
are shown in Fig 2, panel B.
Joint kinetics of HCV-RNA and ALT
Mathematical modeling showed no association between the viral kinetic and the ALT kinetics
parameters (all correlation coefficients <0.4) in the overall population, including the loss-rate
Fig 2. Predicted kinetic profiles obtained by simulations from the viral and ALT kinetic models. (panel A) Different viral kinetics according to
HCV-genotypes, NS5A-inhibitors and interferon administration, (panel B) Different ALT kinetics according to NS5A-inhibitors and interferon
administration. ALT, alanine transaminase; IFN, interferon.
https://doi.org/10.1371/journal.pone.0177352.g002
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of infected-cell δ and the ALT normalization rate λ (S1 and S2 Figs). This remained true when
analyzing separately patients receiving IFN+TVR and all-DAA (S1 and S2 Figs). Because the
kinetics of viral decline was more profound in patients treated with IFN+TVR while the ALT
decline was slower, it is not surprising to find that, for a given level of viral-load reduction, the
corresponding level of ALT decline is much larger in patients treated with IFN-free regimen
than in patients treated with IFN+TVR (Fig 2, panels A and B). This is also illustrated in Fig 3,
where the predicted levels of ALT and HCV-RNA at different time-points are represented. For
none of these time-points, the ALT decline levels were found correlated with HCV-RNA
decline, even when data were analyzed separately for each treatment group (not shown). This,
in other words, suggests that the decline of ALT and HCV-RNA are not reflecting similar
mechanisms, and that these mechanisms may be different in IFN-treated and all-DAA.
Discussion
To our knowledge, this is the first study analyzing and comparing the different kinetics of
HCV-RNA and ALT during all-DAA treatments, unveiling the effect of a specific DAA-class.
We focused our study on GT-1 patients with cirrhosis, a critical population of patients with
peculiar physio-pathological and anatomical characteristics, poorly studied for viral kinetics.
Our mathematical inference predicted a markedly faster and sharper ALT kinetic during
all-DAA treatment than with TVR+PR, as well as a lower ALT steady-state at week-4.
In the context of IFN-based therapy, modeling papers tend to support a correlation between
HCV-RNA and ALT kinetics [4], though with large inter-patients variability according to liver
status [12]. This correlation was explained by IFN use, that acts by establish a non-virus-
Table 3. Cox analysis for factors influencing ALT normalization during treatment.
Variables Hazard ratio of achieving normal ALT
Crude Adjusteda Adjustedb
HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value
pegIFN administration (0c vs. 1) 0.34 (0.21–0.54) <0.0001 0.29 (0.17–0.50) <0.0001 - -
HCV subtype (1ac vs. 1b) 1.39 (0.94–2.06) 0.098 1.32 (0.88–1.98) 0.176 0.89 (0.58–1.36) 0.581
Baseline ALT 0.99 (0.99–0.00) 0.001 0.99 (0.99–0.99) <0.0001 0.99 (0.99–0.99) <0.0001
NS5A-inhibitors administration (0c vs. 1) 3.41 (2.27–5.13) <0.0001 - - 3.51 (2.24–5.48) <0.0001
HCV-RNA decay BL-2 weeks
(per 1 log10 increase)
1.27 (0.98–1.66) 0.076 1.04 (0.76–1.44) 0.796 1.14 (0.82–1.58) 0.441
Baseline HCV-RNA (per 1 log10 increase) 0.69 (0.53–0.89) 0.004 0.76 (0.54–1.07) 0.115 0.73 (0.51–1.04) 0.080
Previous treatment experience
Naïvec 1 - - - - -
Relapser 0.85 (0.48–1.52) 0.588 - - - -
Non responder 0.77 (0.47–1.26) 0.297 - - - -
Other 0.83 (0.36–1.95) 0.676 - - - -
Previous PI experience (0c vs. 1) 1.30 (0.63–2.67) 0.482 - - - -
Favorable IL28B genotype (CCc vs. CT/TT) 0.66 (0.33–1.31) 0.232 - - - -
Ribavirin co-administration 0.58 (0.37–0.93) 0.025 1.06 (0.65–1.74) 0.822 0.71 (0.44–1.16) 0.168
a Adjusted for pegIFN administration, HCV-RNA decay BL-2w, baseline HCV-RNA, ribavirin administration.
b Adjusted for NS5A-inhibitors administration, HCV-RNA decay BL-2w, baseline HCV-RNA, ribavirin administration.
c Reference group (dummy).
ALT, alanine transaminase; BL, baseline; CI, confidence interval; HR, hazard ratio; pegIFN, pegylated interferon; PI, protease inhibitors. Normal ALT values
were considered as <55 IU/ml in men, and <45 IU/ml in women. Only factors with p<0.100 in univariate analysis were included in multivariate analysis. HR
in boldface represents factors having a p-value <0.050.
https://doi.org/10.1371/journal.pone.0177352.t003
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specific antiviral state[15], ultimately leading to a progressive clearance of serum HCV-RNA
mediated by both clearance of circulating virions (first-phase) and, afterwards, by the death or
clearance of productively-infected hepatocytes (second-phase)[1], eventually leading to serum
ALT increase. Indeed, previous kinetics studies in IFN-treated patients showed a positive cor-
relation between lower infected-cell death (δ) and persistently normal ALT values [16].
The typical ALT decay expected in patients with elevated ALT during effective IFN-treat-
ment would thus be a superposition of two trends: 1) an early ALT decline due to initial viral
clearance; and 2) a slower increase during the first 4–8 treatment weeks due to IFN-activity, 3)
reversible after EOT in sustained virologic responders. We indeed observed this fluctuating
ALT decay during TVR+PR treatment, when the initial ALT decay was followed by possible
re-alteration and, lastly, by ALT normalization after EOT.
Notably, after achieving SVR, 73.1% of TVR+PR patients had normal ALT values, a signifi-
cantly lower proportion respecting to all-DAAs treated patients (92%), but still higher of the
67% observed in cirrhotic patients receiving only IFN[12], supporting a further activity of
TVR decay and ALT normalization. Indeed, recently DAAs, and TVR in primis, were pro-
posed by kinetic studies to act by progressive reduction of intracellular viral-RNA down to its
disappearance (“cell-cure”), rather than by inducing cell-death[7, 8]. The results of our study
support this hypothesis, by demonstrating a biphasic ALT decline in which only ALT decline
and normalization were observed: “healthy” ALT levels were always achieved during all-DAA
treatment before complete HCV-RNA clearance, and then maintained until EOT.
The positive effects of all-DAA regimens on ALT kinetics was not simply an effect of a
more profound HCV-RNA decay, and, consequently, of a sharper reduction in HCV-related
pro-inflammatory status[17]. Indeed, the improved ALT decline at each analyzed time point
during all-DAA treatments was confirmed also after normalization for HCV-RNA decay,
again supporting an independent process of cell-cure by DAAs.
Fig 3. Decrease of viral load and ALT at different time points under treatment according to NS5A-
inhibitors and interferon administration. These graphs shows the median of predictions of ALT and
HCV-RNA in different groups of treatment obtained by simulations from the parameter estimates of the two
models. ALT, alanine transaminase; IFN, interferon.
https://doi.org/10.1371/journal.pone.0177352.g003
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By analyzing different all-DAA combinations, we demonstrated, for the first time to our
knowledge, a significant enhancement of ALT declines by NS5A-inhibitors. The use of this
DAA-class also improved the concomitant first-phase of viral kinetics, in agreement with pre-
vious studies that demonstrated a rapid inhibition of viral assembly and secretion by NS5A-
inhibitors[6]. NS5A-inhibitors may thus simultaneously potentiate early HCV-RNA decay by
accelerating viral clearance rate from serum [6], and “anticipate” the process of cell-cure by
more rapid intracellular inhibition of HCV life-cycle, even though this last hypothesis needs to
be confirmed by in vitro studies, not yet available. Notably, both these positive effects were lost
during second-phase, when δ was low and the predicted ALT kinetic profile was no longer
NS5A-dependent.NS5A-inhibitors are now a universal backbone for first-line DAA regimens
[18, 19], and their proposed ability in improving cell-cure further supports their preferential
use as initial treatment for chronic or acute HCV infection, along with their high antiviral
activity and safety profile.
Our study has some points of potential weakness. It does not include a control-population
of patients receiving only PR, though TVR has a poor effect on vRNA kinetics[20], and data
on “pure IFN” treatments are widely available in literature as historical controls. In addition,
ALT values at early time points, such as 48h and week-1 of treatment, were available only for
few TVR+PR treated patients, making the Cox analysis less precise during the first days.
Another point worth to be considered is that we analyzed a population of cirrhotic patients,
in whom liver architecture is altered, and both HCV-RNA and ALT decays can be affected[12,
21, 22]. Even if our results and conclusions may be not directly extended to non-cirrhotic
patients, the presence of cirrhosis seemed not to affect glaringly ALT decline. In a recent study
with SOF+ledipasvir+GS9669/GS-9451, including mostly non-cirrhotic patients, ALT normal-
ization was achieved in 90% of patients by day-14 [14], vs. 85% of our all-DAA patients. Differ-
ently from ALT, viral kinetics was generally reduced in our study. Our free-virus clearance
rate value is lower than previous estimates (c<8 vs. c = 22.3 day-1)[6], maybe as consequence
of advances cirrhosis and/or few early sampling-points. Second-phase was also quite slow and
associated with poor response rates at week-4, concordantly with previous results in cirrhotic
patients[23]. Whether the absence of correlation between second phase of viral decline and the
normalization rate of ALT also holds in non-cirrhotic patients will need to be examined.
Overall treatment effectiveness ε was 0.998, matching previous results obtained in non-cir-
rhotic patients[7, 24, 25]. However, viral-kinetic response under treatment is not necessarily
correlated with treatment outcome[26], and indeed TVR+PR patients achieved SVR12 only in
66.7% of cases, vs. 93.8% in all-DAAs. In the latter population, SVR12 rates were reduced in
CTP-B patients (88.9%) compared to CTP-A (95.6%), concordant with previous results from
the SOLAR study [27], and more recent data on SOF/DCV in ALLY-1 trial [28], and SOF/vel-
patasvir combination [29]. These results probably depend upon the severe liver alteration in
decompensated patients, that deeply affect blood perfusion and metabolic capacity of the resid-
ual liver-tissue, making “cell cure” by DAAs much more difficult. Indeed, in our CTP-B
patients also ALT kinetics was particularly slow, and 12.5% of CTP-B patients reached EOT
with still altered ALT levels vs. only 1.6% of CTP-A patients; p = 0.08.
In summary, we provided a detailed analysis of HCV-RNA and ALT kinetics profiles in cir-
rhotic GT-1 patients treated with different DAAs-based regimens, with particular attention to
the effect of NS5A-inhibitors use and highlighting differences with previous IFN-containing
regimens. Our results uncovered a strikingly fast ALT normalization in patients receiving
NS5A-inhibitors, in contrast with a persistent ALT alteration in patients receiving IFN, inde-
pendent by HCV-RNA clearance. Considering serum ALT levels as a surrogate parameters of
hepatocyte turnover [30, 31], the DAA-driven “sparing” and curing of liver cells (differently by
the cytopathic effect of IFN) may provide an intriguing rationale for these results.
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